These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 18566220)

  • 1. KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling.
    Feng R; Ma H; Hassig CA; Payne JE; Smith ND; Mapara MY; Hager JH; Lentzsch S
    Mol Cancer Ther; 2008 Jun; 7(6):1494-505. PubMed ID: 18566220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo.
    Hassig CA; Symons KT; Guo X; Nguyen PM; Annable T; Wash PL; Payne JE; Jenkins DA; Bonnefous C; Trotter C; Wang Y; Anzola JV; Milkova EL; Hoffman TZ; Dozier SJ; Wiley BM; Saven A; Malecha JW; Davis RL; Muhammad J; Shiau AK; Noble SA; Rao TS; Smith ND; Hager JH
    Mol Cancer Ther; 2008 May; 7(5):1054-65. PubMed ID: 18483295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage.
    Feng R; Oton A; Mapara MY; Anderson G; Belani C; Lentzsch S
    Br J Haematol; 2007 Nov; 139(3):385-97. PubMed ID: 17910628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of KD5170: a novel mercaptoketone-based histone deacetylase inhibitor.
    Payne JE; Bonnefous C; Hassig CA; Symons KT; Guo X; Nguyen PM; Annable T; Wash PL; Hoffman TZ; Rao TS; Shiau AK; Malecha JW; Noble SA; Hager JH; Smith ND
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6093-6. PubMed ID: 18954983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY; Dai Y; Grant S
    Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib.
    Sutheesophon K; Kobayashi Y; Takatoku MA; Ozawa K; Kano Y; Ishii H; Furukawa Y
    Acta Haematol; 2006; 115(1-2):78-90. PubMed ID: 16424655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells.
    Chauhan D; Li G; Podar K; Hideshima T; Mitsiades C; Schlossman R; Munshi N; Richardson P; Cotter FE; Anderson KC
    Blood; 2004 Oct; 104(8):2458-66. PubMed ID: 15217830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
    Duan J; Friedman J; Nottingham L; Chen Z; Ara G; Van Waes C
    Mol Cancer Ther; 2007 Jan; 6(1):37-50. PubMed ID: 17237265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.
    Maiso P; Carvajal-Vergara X; Ocio EM; López-Pérez R; Mateo G; Gutiérrez N; Atadja P; Pandiella A; San Miguel JF
    Cancer Res; 2006 Jun; 66(11):5781-9. PubMed ID: 16740717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells.
    Maggio SC; Rosato RR; Kramer LB; Dai Y; Rahmani M; Paik DS; Czarnik AC; Payne SG; Spiegel S; Grant S
    Cancer Res; 2004 Apr; 64(7):2590-600. PubMed ID: 15059916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage.
    Premkumar DR; Jane EP; Agostino NR; DiDomenico JD; Pollack IF
    Mol Carcinog; 2013 Feb; 52(2):118-33. PubMed ID: 22086447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HDAC inhibitor L-carnitine and proteasome inhibitor bortezomib synergistically exert anti-tumor activity in vitro and in vivo.
    Huang H; Liu N; Yang C; Liao S; Guo H; Zhao K; Li X; Liu S; Guan L; Liu C; Xu L; Zhang C; Song W; Li B; Tang P; Dou QP; Liu J
    PLoS One; 2012; 7(12):e52576. PubMed ID: 23285100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib.
    Yu C; Rahmani M; Dent P; Grant S
    Exp Cell Res; 2004 May; 295(2):555-66. PubMed ID: 15093752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors.
    Jóna A; Khaskhely N; Buglio D; Shafer JA; Derenzini E; Bollard CM; Medeiros LJ; Illés A; Ji Y; Younes A
    Exp Hematol; 2011 Oct; 39(10):1007-1017.e1. PubMed ID: 21767511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma.
    Chen MC; Huang HH; Lai CY; Lin YJ; Liou JP; Lai MJ; Li YH; Teng CM; Yang CR
    Oncotarget; 2016 Jan; 7(1):402-17. PubMed ID: 26587975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PS-341 and histone deacetylase inhibitor synergistically induce apoptosis in head and neck squamous cell carcinoma cells.
    Kim J; Guan J; Chang I; Chen X; Han D; Wang CY
    Mol Cancer Ther; 2010 Jul; 9(7):1977-84. PubMed ID: 20571067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pan-histone deacetylase inhibitor CR2408 disrupts cell cycle progression, diminishes proliferation and causes apoptosis in multiple myeloma cells.
    Baumann P; Junghanns C; Mandl-Weber S; Strobl S; Oduncu F; Schmidmaier R
    Br J Haematol; 2012 Mar; 156(5):633-42. PubMed ID: 22211565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo.
    Dasmahapatra G; Lembersky D; Kramer L; Fisher RI; Friedberg J; Dent P; Grant S
    Blood; 2010 Jun; 115(22):4478-87. PubMed ID: 20233973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bortezomib and SAHA synergistically induce ROS-driven caspase-dependent apoptosis of nasopharyngeal carcinoma and block replication of Epstein-Barr virus.
    Hui KF; Lam BH; Ho DN; Tsao SW; Chiang AK
    Mol Cancer Ther; 2013 May; 12(5):747-58. PubMed ID: 23475956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Study on histone deacetylase inhibitor LBH589 induces apoptosis of multiple myeloma cells and its reversal of drug resistance mechanism].
    Zhang L; Ma YP; Jia G
    Zhonghua Xue Ye Xue Za Zhi; 2012 Nov; 33(11):926-31. PubMed ID: 23363750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.